FIG. 6.

Modification of cellular susceptibility to infection. Panel A: pretreatments with TAT⁰ (•), TAT-Pd⁰ (○), or TAT-Cd⁰ (▵). TAT-Cd⁰ was administered in the presence of a 10-fold molar excess of DTT to keep the peptide in the reduced or monomeric form. Panel B: pretreatments with TAT-C⁻ (•), n_50,51TAT-C⁻ (○), or n_55,56TAT-C⁻ (▵). Following pretreatments of Vero cells for 1 h at 37°C, free peptide was rinsed off and cultures were infected with hrR3 (MOI, 0.01) in the absence of peptide for 1 h at 37°C, treated with pH 3 citrate buffer, and scored for β-galactosidase activity 6 h later. The data points represent the means of triplicate determinations with standard errors of the means.